Tetraphase’s eravacycline gets FDA fast track status
Currently, the company is evaluating the safety and efficacy of eravacycline in a Phase III clinical program, which includes two trials. The IGNITE 1 trial is assessing the
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
This patent provides Mersana broad coverage for its polymer-based Fleximer-ADC platform technology. The patent covers Fleximer-drug conjugates that can be linked to an antibody to create next-generation antibody